Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing CreamGlobeNewsWire • 12/13/21
Arcutis Announces Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/04/21
New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology CongressGlobeNewsWire • 09/30/21
New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) CongressGlobeNewsWire • 09/27/21
Arcutis Announces Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/05/21
Arcutis Announces Additions to its Investor Relations and Communications TeamGlobeNewsWire • 08/02/21
All You Need to Know About Arcutis Biotherapeutics, Inc. (ARQT) Rating Upgrade to BuyZacks Investment Research • 07/23/21
Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate PsoriasisGlobeNewsWire • 07/21/21
Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic DermatitisGlobeNewsWire • 07/12/21
Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema StudyBenzinga • 07/01/21
Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for VitiligoGlobeNewsWire • 07/01/21
Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process TechnologiesGlobeNewsWire • 06/23/21
Arcutis Announces First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/04/21
Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring SymposiumGlobeNewsWire • 05/03/21
Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment InitiationBenzinga • 04/23/21
Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021GlobeNewsWire • 04/23/21
Arcutis Biotherapeutics to Present New Roflumilast Data at The American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX)GlobeNewsWire • 04/19/21